Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: Age-related macular degeneration (AMD) is the main cause of visual loss in the elderly population. With the use of anti-vascular endothelial growth factor, the visual outcomes of exudative AMD patients have been improved. This study was aimed at assessing the quality of life (QoL) of exudative AMD patients treated with ranibizumab and at determining its drivers in a real-life setting. Methods: We performed a national, cross-sectional, observational survey based on questionnaires sent to members of French associations relative to AMD between December 2012 and March 2013. Patients suffering from exudative AMD with at least one intravitreal injection of ranibizumab within the last 6 months were included. Demographics, AMD characteristics, visual acuity (VA) and past and ongoing treatments were collected. The 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) was self-administered. A multivariate model was used to identify QoL drivers. Results: 416 questionnaires fulfilled the complete criteria for both QoL and cost analyses. The mean age of exudative AMD patients was 78.0 years and bilateral involvement was reported in 60.4%. The overall mean QoL score was 53.4. Mental health, driving and role difficulties were the most widely affected domains. After bivariate analyses, long-term illness status, worse VA and higher number of unpaid aids were associated with worse QoL, with odds ratios of 2.4, 5.2 and 11.6, respectively. The mean cost per year and per patient was 1,741 EUR. The main components of costs were aids and services and the purchase of visual equipment. Conclusions: The main predictors of QoL in exudative AMD patients treated with ranibizumab are VA outcomes, home healthcare and social services provided to the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, only three studies using post-2010 cost data reported annual direct non-medical costs [34, 37, 38].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239
Cohen, S. Y., Mimoun, G., Oubraham, H., Zourdani, A., Malbrel, C., Queré, S., & Schneider, V. (2013) · Retina · doi:10.1097/iae.0b013e31827b6324 · Cited by 198
Soubrane, G. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.9.1249 · Cited by 155
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Quiroz-Mercado, H., & Mandava, N. (2013) · Retina · doi:10.1097/iae.0000000000000036 · Cited by 154
Oubraham, H., Cohen, S. Y., Samimi, S., Marotte, D., Bouzaher, I., Bonicel, P., Fajnkuchen, F., & Tadayoni, R. (2011) · Retina · doi:10.1097/iae.0b013e3181de5609 · Cited by 151
Cited by
Finger, R. P., Daïen, V., Eldem, B. M., Talks, J. S., Korobelnik, J., Mitchell, P. L. R., Sakamoto, T., Wong, T. Y., Pantiri, K., & Carrasco, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01554-2 · Cited by 163
Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Kamoshita, M., Minami, S., Shinoda, H., Tsubota, K., & Ozawa, Y. (2016) · Scientific Reports · doi:10.1038/srep29619 · Cited by 62
Tuuminen, R., Uusitalo‐Järvinen, H., Aaltonen, V., Hautala, N. M., Kaipiainen, S., Laitamäki, N., Ollila, M., Rantanen, J., Välimäki, S., Sipilä, R., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13501 · Cited by 50
“Two meta-analyses reported a 0.049–0.056% risk for endophthalmitis after intravitreal antiVEFG injections, i.e. about five infections per 10 000 injections (McCannel 2011; Fileta et al. 2014).”
BackgroundInfluentialGale, R. P., Finger, R. P., Eldem, B. M., Aslam, T. M., Barratt, J., Daïen, V., Kodjikian, L., Loewenstein, A., Okada, M., Wong, T. Y., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15201 · Cited by 39
Schippert, A. C., Jelin, E., Moe, M. C., Heiberg, T., & Grov, E. K. (2018) · Gerontology and Geriatric Medicine · doi:10.1177/2333721418801601 · Cited by 33
“Reduction in QoL is associated with wet AMD and has been measured with standardized instruments leaving additional knowledge regarding aspects of the disease (Matamoros et al., 2015; Swamy, Chia, Wang, Rochtchina, & Mitchell, 2009).”
MethodAlvarez-Peregrina, C. C., Sánchez‐Tena, M. Á., Caballe-Fontanet, D., Thuissard, I. J., Gacimartín-García, M. B., & Magán, C. O. (2018) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2018.05.017 · Cited by 28
Fenwick, E., Cheung, C. M. G., Ong, P. G., Tan, G. S. W., Lee, S. Y., Yeo, I. Y. S., Cheng, C., Wong, T. Y., & Lamoureux, E. L. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308541 · Cited by 26
Honda, S., Yanagi, Y., Koizumi, H., Chen, Y., Tanaka, S., Arimoto, M., & Imai, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-92567-4 · Cited by 23
İnan, S., Çetinkaya, E., Duman, R., Doğan, İ., & İnan, Ü. U. (2019) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2018.0195071218 · Cited by 32
Rossouw, P., Guichard, M.-M., & Hatz, K. B. (2020) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12736 · Cited by 23
“The mean near activity subscale score recorded here was higher than for MARINA/ ANCHOR(29) and EQUADE.(30) This might be explained by the improved VA in the better eye.”
Bian, W., Wan, J., Smith, G. D., Li, S., Tan, M., & Zhou, F. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018756 · Cited by 18
“Interviews started with general questions such as ‘Tell me about your experiences and feelings about AMD’.”
MethodInfluentialAlvarez-Peregrina, C. C., Sánchez‐Tena, M. Á., Caballe-Fontanet, D., Thuissard, I. J., Gacimartín-García, M. B., & Magán, C. O. (2018) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2018.09.001 · Cited by 14
Vu, K. V., Mitchell, P. L. R., Detaram, H. D., Burlutsky, G., Liew, G., & Gopinath, B. (2023) · Eye · doi:10.1038/s41433-023-02407-0 · Cited by 13
The effects of age-related macular degeneration on quality of life in a Brazilian population
Roque, A. B., Borges, G. F. D. S., Abe, R. Y., de Souza, O. F., Machado, M. C., Ferreira, T., José, N. K., & de Vasconcellos, J. P. C. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00290-z · Cited by 41
“Therefore, patient-reported outcome measures obtained through questionnaires have been used to measure the effect of eye disorders on health-related QoL (HRQoL) and, more specifically, vision-related QoL (VRQoL) [8].”
BackgroundResultKorobelnik, J.-F., Delcourt, C., Creuzot-Garcher, C., Melaine, A., Chassetuillier, J., Lejeune, A., Bénard, S., & Dupont-Benjamin, L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1971416 · Cited by 9
“Hospitalizations and surgery Mean (SD) 6,396 (14,409) 5,235 (13,250) Median (IQR) 490 (0–6,407) 22 (0–3,640) Treatment Mean (SD) 6,847 (4,717) 1,156 (3,699) Median (IQR) 5,602 (3,555–8,717) 561 (237–1,154) Medical fees (outpatient visits) Mean (SD) 1,858 (1,686) 295 (296) Median (IQR) 1,441 (810–2,298) 238 (108–390) P…”
Bian, W., Wan, J., Tan, M., Su, J., Yuan, Y., Wang, Z., & Li, S. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01561-3 · Cited by 11
Caballe-Fontanet, D., Alvarez-Peregrina, C. C., Busquet-Duran, N., Pedemonte-Sarrias, E., & Sánchez‐Tena, M. Á. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17186751 · Cited by 9
“It is validated for AMD [20,21] and adapted to Spanish [22].”
BackgroundMarakis, T. P., Koutsandrea, C., & Πούλου, Μ. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120972625 · Cited by 9
Ghoshal, R., Kaur, S., Fadzil, N. M., Ghosh, S., Ngah, N. F., & Aziz, R. A. B. A. (2018) · Sains Malaysiana · doi:10.17576/jsm-2018-4710-21 · Cited by 7
“Thus, there is a recent trend to evaluate the quality of life in n-AMD and its treatment effect (Bertelmann et al. 2016; Matamoros et al. 2015; Yuzawa et al. 2013).”
BackgroundResultInfluentialChoi, S. W., Kim, Y. E., & Kim, J. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300062 · Cited by 6
Bian, W., Wang, Z., Wan, J., Zhang, F., Wu, X., Li, X., & Luo, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064892 · Cited by 7
Visual function and biofeedback training of patients with central vision loss: a review
Deng, Y., Wang, J., Li, Y., & Liu, Z. (2023) · International Journal of Ophthalmology · doi:10.18240/ijo.2023.05.21 · Cited by 6
Vottonen, P. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13706 · Cited by 6
“All of these factors cause severe loss of quality of life (Sahel et al. 2007; Soubrane et al. 2007; Matamoros et al. 2015).”
BackgroundFeline uterine prolapse (a case report).
Bruinsma, D. L. (1981) · PubMed · Cited by 4
Patient-Perceived Benefit of Treatment in Polypoidal Choroidal Vasculopathy: A Pilot Study
Ghoshal, R., Sharanjeet-Kaur, S., Fadzil, N. M., Ghosh, S., Ngah, N. F., & Aziz, R. A. B. A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176378 · Cited by 3
“reported that mental health and dependency were some of the most affected NEI-VFQ-25 subscales in patients with n-AMD undergoing anti-VEGF [29].”
BackgroundHilal, A., Bazarah, M., & Kapoula, Z. (2021) · Brain Sciences · doi:10.3390/brainsci12010036 · Cited by 3
“sent out questionnaires to exudative ARMD patients with an inclusion criterion that they had received at least one intravitreal injection of Ranibizumab within the last 6 months [19].”
BackgroundIsmayilova, I., Turdaliyeva, B., Aldasheva, N., & Veselovskaya, N. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i6.13580 · Cited by 7
Archambault, S. D., Nichols, M. M., McCullum, J. C., Zhang, Y., Steinberger, E. E., & Ramsey, D. J. (2023) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1795_23 · Cited by 3
“[3‑19] However, patients undergoing treatment for nAMD must contend with real physical, [20,21] psychological, [6,20,22] and financial [23,24] burdens associated with treatment.”
BackgroundVu, T. A., Fenwick, E., Man, R. E. K., Thakur, S., Tan, A. C. S., Cheung, C. M. G., Gupta, P., & Lamoureux, E. L. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-325713 · Cited by 2
Kabedi, N. N., Kayembe, D. L., & Mwanza, J.-C. (2020) · Seminars in Ophthalmology · doi:10.1080/08820538.2020.1774623 · Cited by 3
“Findings of both OCT and ICGA in patients with PCV have concurred to suggest that PCV, particularly with type I choroidal neovascularization, is a form of AMD.14,15 However, PCV and typical AMD have different clinical courses and functional outcomes,16 which would logically lead to differences in the way they impact t…”
ResultInfluentialFlindris, K., Chatzipetrou, C., Papafotiou, E., Kaliardas, A., Koumpoulis, I., & Melissourgos, I. (2025) · Cureus · doi:10.7759/cureus.91004 · Cited by 1
“In practical terms, communicating to patients that continuing regular injections can preserve not just their sight but also their independence and lifestyle may motivate adherence [23].”
Neovascular age-related macular degeneration in Austria
TargetAMD Group, STOLBA, U., Ansari‐Shahrezaei, S., Hagen, S., Stattin, M., Schmid, S., Kropp, M., Harmening, N., & Thumann, G. (2017) · Spektrum der Augenheilkunde · doi:10.1007/s00717-017-0356-7 · Cited by 1
Willmington, C., Kirby, A., & Murphy, A. (2025) · Health Economics Review · doi:10.1186/s13561-025-00707-7
“3 and Supplementary Table 2), across France ( n = 5) [36, 38, 41, 42, 45], Germany ( n = 3) [37, 41, 42], Italy ( n = 3) [35, 42, 44], Spain ( n = 3) [34, 40, 41] and the UK ( n = 3) [39, 41, 43].”
Kristianto, B., Djelantik, A. A. A. S., Andayani, A., Triningrat, A. A. M. P., Juliari, I. G. A. M., & Widiana, I. G. R. (2021) · International Journal of Retina · doi:10.35479/ijretina.2021.vol004.iss002.168
“The questionnaire NEI-VQF 25 is a tool that can help to make an assessment on the quality of life of the AMD itself (Matamoros, 2015).”
MethodCorrelation between corneal tomography and postphacoemulsification positive dysphotopsia
Shrief, M. M., Mazar, H., & Bassiouni, A. (2022) · Menoufia Medical Journal · doi:10.4103/mmj.mmj_229_21
Application of synthetic biology in age-related and neurodegenerative disease
Ghosh, S., Kundu, S., Jana, R., Basu, B., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33649-2.00011-3
Quality of Life in Patients with Posterior Segment Eye Diseases
Khorrami‐Nejad, M., Narooie-Noori, F., Al-khafaji, Q., Hashemian, H., Balal, S., Dohlman, T. H., & Daya, S. M. (2026) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v21.18249
“Matamoros et al [10] 2015 • NEI-VFQ-25 416 • For patients with exudative AMD treated with ranibizumab, the key predictors of QoL included VA outcomes, home healthcare, and social support services.”
InfluentialNowak, M., Cybulska, A. M., Derezińska, A., Grochans, E., Pańczyk, M., Kęcka, K., & Rachubińska, K. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1731481
“Communicating to patients that maintaining regular injections can preserve not only their vision but also their independence and quality of life may help enhance adherence (30, 31).”
Sleath, B. L., Zhang, A. Y., Carpenter, D. M., Adjei, A., Annis, I. E., Garcia, N., Olson, D., & Dobbin, K. (2026) · Optometry and Vision Science · doi:10.1002/ovs2.70070
Metadata
- Authors
- Matamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., & Leveziel, N.
- Affiliations
- Centre Hospitalier Universitaire de Poitiers (FR)
- IQVIA (United States) (US)
- Retina France (FR)
- Université Paris-Est Créteil (FR)
- Université de Poitiers (FR)
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 234
- Issue
- 3
- Pages
- 151-159
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W1873618078
- Cited by
- 40
- References
- 24
- Citations by year
- 2026: 3 · 2025: 4 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 1 · 2018: 6 · 2017: 2 · 2016: 2
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Ophthalmologica (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Retina France
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- neovascular age-related macular degeneration, quality of life, ranibizumab, anti-VEGF therapy, visual acuity, NEI VFQ-25, mental health, driving impairment, chronic disease, home health care, social services, cost of care, visual aids, elderly patients
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Cross-Sectional Studies, Exudates and Transudates, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Visual Acuity, Cost of Illness, Sickness Impact Profile, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

